Fed Chairman Warsh Contributing to Volatility, Says Economist Claudia Sahm
Original Report
Claudia Sahm, chief economist at New Century Advisors, says uncertainty about the Federal Reserve’s interest rate decision comes from “a Fed Chair who was gone really low information on how he’s...
Claudia Sahm, chief economist at New Century Advisors, says uncertainty about the Federal Reserve’s interest rate decision comes from “a Fed Chair who was gone really low information on how he’s thinking about policy.” (Source: Bloomberg)
Glass House Analysis
Central bank policy decisions made in boardrooms cascade through the economy in ways that touch everyone. A quarter-point rate change might seem abstract, but it determines whether young families can afford homes, whether businesses can afford to hire, and whether retirees see meaningful returns on their savings. The tension between fighting inflation and maintaining employment represents a fundamental tradeoff in economic policy—one that invariably creates winners and losers.
The implications extend beyond the immediate news cycle. Every economic development creates ripples that affect employment, prices, and opportunities in ways that may not be immediately visible but are deeply felt. By tracking these connections, we can better understand how the economy truly works—not as an abstract machine, but as a human system shaped by and shaping the lives of millions.
Enjoyed this analysis?
Get the Glass House Briefing every morning—market news that actually makes sense, delivered free to your inbox.
No spam. Unsubscribe anytime.
More Stories
Bitcoin and ethereum prices today, Wednesday, July 29, 2026: Crypto investors watching the Fed decision closely
Investors are selling Meta as it heads to its earnings report
Oil prices jump more than 6% after Trump says U.S. will hit Iran hard
Oil rose sharply amid renewed tensions in the Middle East after Iran launched an attack on U.S. forces using ballistic missiles.
Why shareholders are suing Novo Nordisk over next-generation weight-loss drug
Investors claim Novo Nordisk misled the market about CagriSema's tolerability, after disappointing clinical trial results wiped billions off its market cap.